Equities Analysts Offer Predictions for Annexon Q4 Earnings

Posted by Francis Steltz on Nov 12th, 2026

Annexon, Inc. (NASDAQ:ANNX – Free Report) – Analysts at HC Wainwright decreased their Q4 2026 earnings estimates for shares of Annexon in a research note issued on Tuesday, November 10th. HC Wainwright analyst A. Ghosh now forecasts that the company will post earnings per share of ($0.28) for the quarter, down from their prior forecast of ($0.24). HC Wainwright currently has a “Buy” rating and a $14.00 target price on the stock. The consensus estimate for Annexon’s current full-year earnings is ($1.05) per share. HC Wainwright also issued estimates for Annexon’s Q1 2027 earnings at ($0.26) EPS, Q2 2027 earnings at ($0.27) EPS, Q3 2027 earnings at ($0.27) EPS, Q4 2027 earnings at ($0.19) EPS, FY2027 earnings at ($0.99) EPS, FY2028 earnings at ($0.26) EPS and FY2030 earnings at $1.61 EPS.

Annexon (NASDAQ:ANNX – Get Free Report) last released its quarterly earnings data on Monday, November 9th. The company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.03.

A number of other equities analysts have also recently issued reports on the stock. Wall Street Zen cut shares of Annexon from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Annexon in a report on Thursday, October 15th. Citigroup initiated coverage on shares of Annexon in a research note on Tuesday, July 21st. They set a “market underperform” rating for the company. Citizens Jmp upgraded Annexon from an “underperform” rating to a “market perform” rating in a report on Thursday, August 13th. Finally, Needham & Company LLC increased their target price on Annexon from $11.00 to $25.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Six analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $15.29.

Read Our Latest Analysis on Annexon

Annexon Stock Performance

NASDAQ ANNX opened at $4.19 on Thursday. The company has a market capitalization of $794.34 million, a P/E ratio of -4.03 and a beta of 1.43. The company has a debt-to-equity ratio of 0.35, a current ratio of 5.79 and a quick ratio of 5.53. Annexon has a 1-year low of $2.54 and a 1-year high of $7.18. The business has a 50 day moving average price of $4.06 and a 200 day moving average price of $5.13.

Institutional Trading of Annexon

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. purchased a new position in Annexon in the third quarter valued at about $41,000. Sowell Financial Services LLC bought a new stake in shares of Annexon in the third quarter worth $57,000. Integrated Wealth Concepts LLC raised its holdings in Annexon by 32.3% in the second quarter. Integrated Wealth Concepts LLC now owns 13,537 shares of the company’s stock valued at $77,000 after acquiring an additional 3,305 shares in the last quarter. Forefront Analytics LLC acquired a new stake in Annexon in the second quarter valued at $81,000. Finally, Coastal Bridge Advisors LLC acquired a new stake in Annexon in the second quarter valued at $97,000.

Insider Transactions at Annexon

In other news, CEO Douglas Love acquired 26,065 shares of the business’s stock in a transaction on Thursday, September 24th. The shares were purchased at an average price of $3.83 per share, for a total transaction of $99,828.95. Following the acquisition, the chief executive officer directly owned 390,476 shares of the company’s stock, valued at $1,495,523.08. This represents a 7.15% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 10.31% of the stock is owned by company insiders.

Latest Annexon News

Here’s some of the latest news about ANNX:

Positive Sentiment: A separate report cited a consensus price target of $15.29, above the analyst’s $14 target. Annexon consensus price target article
Neutral Sentiment: HC Wainwright kept its Buy rating and $14 price target despite revising several estimates.
Negative Sentiment: HC Wainwright cut its FY2027 EPS forecast to a loss of $0.99 per share from a loss of $0.69, and its FY2028 estimate to a loss of $0.26 from $0.16. It also lowered estimates for Q4 2026 and each quarter of 2027, pointing to greater expected losses in the near term.

Annexon Company Profile

(Get Free Report)

Annexon is a clinical-stage biopharmaceutical company developing antibody-based therapies for diseases driven by the complement system, a part of the immune system involved in inflammation and tissue damage. The company focuses on the classical complement pathway, which it aims to inhibit selectively. Its investigational programs are designed for complement-related autoimmune, inflammatory and neurodegenerative conditions. These include treatments being studied for disorders affecting the nervous system and the eye.